t( 8;21 )

Molecular Haematology


Description

The chromosomal translocation t( 8;21 ) has been shown to be important in clinical practice and can identify a subgroup of AML with relatively good prognosis. It is found in approximately 20% of AML-M2, and responds well to treatment with cytosine arabinoside. It is suggested that patients with this translocation do not benefit from bone marrow transplantation.The molecular consequence of a t( 8;21 ) is an AML-ETO gene fusion. This fusion gene can be detected in cases of AML lacking t( 8;21 ) by classical cytogenetics. The breakpoints in t( 8;21 ) are highly conserved, so can be detected by RT-PCR.


Indications

Used to monitor cases known to have t( 8;21 ).


Sample Type

5ml EDTA blood or bone marrow, less than 48 hrs old.


Turnaround Time

Within 4 weeks


Testing Frequency

As required.


External Notes

Level of detection 1 leukaemic cell in 105 normal cells.


Please note: the above information is subject to change and we endeavour to keep this website up to date wherever necessary.

Your contact for this test

team

Rosalie Ward BSc (Hons) Biomedical Science, MSc Pathological Science, FIBMS

Section Lead - Cellular Immunology/Cell Markers

You are enquiring about

t( 8;21 )